This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Kinerase® Partners With The American Breast Cancer Foundation

Stocks in this article: VRX

BRIDGEWATER, N.J., Oct. 2, 2012 /PRNewswire/ -- Kinerase, a sub-brand of Valeant Pharmaceuticals North America, is pleased to announce their partnership with the American Breast Cancer Foundation for the month of October. The brand will be donating 20 percent of the proceeds from their two new anti-aging products, Advanced Cream and Advanced Lotion, when purchased at Ulta, the premium beauty retailer, between October 1 and October 31, 2012.

New to the line, Kinerase Advanced Lotion and Cream both moisturize skin while supporting its natural production of hyaluronic acid. Along with visible improvement in the appearance of fine lines and wrinkles, skin is smoother and more hydrated, with a more even tone.

"We are so proud to partner with the American Breast Cancer Foundation," said Alissa Lynch, VP & General Manager Valeant Pharmaceuticals. "By donating a portion of the sales from our in-demand new products, Kinerase Advanced Cream and Lotion, we hope to not only increase brand awareness but make a difference in the fight against breast cancer."

The American Breast Cancer Foundation (ABCF) provides screenings, diagnostic testing and treatment services to individuals and medical clinics either at a reduced fee or free of charge nationwide. Over 50 percent of those who receive assistance from the foundation are already diagnosed with breast cancer. Partnering with the ABCF provides the opportunity for both Kinerase and customer to advance the foundation's mission of financial assistance to these patients.


To participate in the donation program, purchase Kinerase ® Advanced Lotion and Advanced Cream at Ulta from October 1 – 31, 2012.


Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant has over 20 years of experience in dermatological science.  More information about Valeant can be found at

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,655.58 +298.71 1.72%
S&P 500 2,044.19 +31.30 1.56%
NASDAQ 4,716.2720 +71.96 1.55%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs